Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807)-Reference-Cited by-同舟云学术

Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807)

Published:2015-01 Issue:2 Volume:94 Page:e249
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Zhao Hong-Yun,Chen Gong-Yan,Huang Yan,Li Xiao-li,Feng Ji-Feng,Shi Mei-Qi,Cheng Ying,Ma Li-Xia,Zhang Yi-Ping,Gu Cui-Ping,Song Xiang-Qun,Zhou Da,Zhang Li

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference45 articles.

1. Clinical features of 5628 primary lung cancer patients: experience at Mayo Clinic from 1997 to 2003;Yang;Chest,2005

2. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J Clin Oncol,2006

3. The National Institute on Aging and the National Cancer Institute SEER collaborative study on comorbidity and early diagnosis of cancer in the elderly;Havlik;Cancer,1994

4. Global cancer statistics in the year 2000;Parkin;Lancet Oncol,2001

5. Chemotherapy for elderly patients with advanced non-small-cell lung cancer: the Multicenter Italian Lung Cancer in the Elderly Study (MILES) phase III randomized trial;Gridelli;J Natl Cancer Inst,2003

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A pilot study identifying a potential plasma biomarker for determining EGFR mutations in exons 19 or 21 in lung cancer patients;Molecular Medicine Reports;2017-04-28

2. A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients;Cancer Chemotherapy and Pharmacology;2015-12-26